Rapport Therapeutics Presents Data Demonstrating Consistent Association Between Decreases in RNS Measured Long Episodes and Meaningful Reductions in Clinical Seizures
December 06, 2024 12:01 ET
|
Rapport Therapeutics, Inc.
Rapport presents new data on the linear relationship between a seizure biomarker used in the company's RAP-219 POC trial and clinical seizures.
Shepherd Ave Capital Acquisition Corp Announces Closing of Initial Public Offering
December 06, 2024 12:00 ET
|
Shepherd Ave Capital Acquisition Corporation
Wilmington, DE, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Shepherd Ave Capital Acquisition Corporation (NASDAQ: SPHAU) (“SPHA” or the “Company”) announced today that it closed its initial public offering...
Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations
December 06, 2024 11:06 ET
|
Psyence Group Inc.
TORONTO, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) hereby announces that it has entered into an addendum to the previously announced...
Linkers Industries Limited Announced Closing of Initial Public Offering
December 06, 2024 11:00 ET
|
Linkers Industries Limited
New York, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Linkers Industries Limited (Nasdaq: LNKS) (the “Company”), a manufacturer and a supplier of wire/cable harnesses with operation in Malaysia, today...
GSI Technology to Participate Virtually in the 27th Annual Needham Growth Conference on January 17, 2025
December 06, 2024 10:48 ET
|
GSI Technology, Inc.
SUNNYVALE, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- GSI Technology, Inc. (Nasdaq: GSIT), the inventor of the Associative Processing Unit (APU), a paradigm shift in AI and HPC processing providing...
Lee Enterprises and Perplexity Partner to Revolutionize Local News with AI Innovation
December 06, 2024 09:30 ET
|
Lee Enterprises Inc.
DAVENPORT, Iowa, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Lee Enterprises, Inc. (NASDAQ: LEE), a leading provider of trusted local journalism across the United States, has announced a partnership with...
Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und Wirksamkeitsdaten aus der eNRGy-Studie bekannt
December 06, 2024 09:28 ET
|
Merus N.V.
BIZENGRI® ist die erste und einzige von der FDA zugelassene Therapie speziell für Adenokarzinome der Bauchspeicheldrüse und nicht-kleinzellige Lungenkarzinome, die NRG1-Genfusionen aufweisen und...
Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en fonction des données de sécurité et d’efficacité issues de l’étude eNRGy
December 06, 2024 09:28 ET
|
Merus N.V.
BIZENGRI® est le premier et unique traitement autorisé par la FDA spécifiquement indiqué dans l’adénocarcinome pancréatique et le cancer du poumon non à petites cellules (CPNPC) avancé, non résécable...
Profound Medical Announces Pricing of US$35 Million Underwritten Public Offering of Common Shares
December 06, 2024 09:04 ET
|
Profound Medical Corp.
BASE SHELF PROSPECTUS IS ACCESSIBLE, AND FINAL PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS, ON SEDAR+ AND ON EDGAR TORONTO, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Profound Medical...
Euronet Announces Appointment of Brad Sprong to Its Board of Directors
December 06, 2024 09:00 ET
|
Euronet Worldwide, Inc.
Euronet (NASDAQ: EEFT) today announced the appointment of Brad Sprong to the Euronet Board of Directors, increasing the board from 10 to 11 members.